Subtopic Deep Dive

AMPK and Tumor Suppression in Cancer
Research Guide

What is AMPK and Tumor Suppression in Cancer?

AMPK acts as an energy sensor that suppresses tumor growth by inhibiting cell proliferation and promoting autophagy through metabolic reprogramming in cancer cells.

AMPK activation inhibits mTOR signaling and enhances energy homeostasis, reducing cancer risk (Hardie et al., 2012; 4260 citations). LKB1 complexes upstream activate AMPK, linking tumor suppression to metabolic control (Hawley et al., 2003; 1616 citations). Diabetes elevates cancer incidence, with AMPK activators like metformin showing protective effects (Giovannucci et al., 2010; 2197 citations).

Curated Papers

Key Challenges

Why It Matters

AMPK targets offer anticancer therapies by countering tumor glycolysis and metabolic reprogramming (Ganapathy-Kanniappan and Geschwind, 2013). Metformin, an AMPK activator, extends mouse lifespan and healthspan, suggesting benefits against age-related cancers (Martín-Montalvo et al., 2013). Hardie (2011) details AMPK's regulation of cell function, impacting diabetes-cancer links (Giovannucci et al., 2010). These connections drive drug development bridging metabolism and oncology.

Key Research Challenges

Upstream Kinase Dysregulation

LKB1 mutations impair AMPK activation in tumors, disrupting energy sensing (Hawley et al., 2003). This reduces tumor suppression despite high AMP levels. Hardie et al. (2012) note inconsistent activation in cancer contexts.

mTOR Pathway Crosstalk

Hypoxia inhibits mTOR via AMPK-TSC but cancer cells evade this (Brugarolas et al., 2004). Balancing growth suppression and survival signals challenges therapy. Hardie (2011) highlights AMPK's broad regulation complicating specificity.

Metabolic Reprogramming Resistance

Tumors resist AMPK-induced autophagy via PI3K/AKT dominance (Huang et al., 2018). Diabetes risk factors exacerbate this (Giovannucci et al., 2010). Ganapathy-Kanniappan and Geschwind (2013) stress targeting glycolysis failures.

Essential Papers

AMPK: a nutrient and energy sensor that maintains energy homeostasis

D. Grahame Hardie, Fiona A. Ross, Simon A. Hawley · 2012 · Nature Reviews Molecular Cell Biology · 4.3K citations

Diabetes and Cancer

Edward L. Giovannucci, David M. Harlan, Michael C. Archer et al. · 2010 · Diabetes Care · 2.2K citations

Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and diabetes treatments. This consensus statement of experts assembled joi...

Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade

Simon A. Hawley, Jérôme Boudeau, Jennifer L. Reid et al. · 2003 · Journal of Biology · 1.6K citations

AMP-activated protein kinase—an energy sensor that regulates all aspects of cell function

D. Grahame Hardie · 2011 · Genes & Development · 1.6K citations

AMP-activated protein kinase (AMPK) is a sensor of energy status that maintains cellular energy homeostasis. It arose very early during eukaryotic evolution, and its ancestral role may have been in...

The PI3K/AKT pathway in obesity and type 2 diabetes

Xingjun Huang, Guihua Liu, Jiao Guo et al. · 2018 · International Journal of Biological Sciences · 1.5K citations

Obesity and type 2 diabetes mellitus are complicated metabolic diseases that affect multiple organs and are characterized by hyperglycaemia. Currently, stable and effective treatments for obesity a...

Tumor glycolysis as a target for cancer therapy: progress and prospects

Shanmugasundaram Ganapathy‐Kanniappan, Jean-François H. Geschwind · 2013 · Molecular Cancer · 1.4K citations

Metformin improves healthspan and lifespan in mice

Alejandro Martín‐Montalvo, Evi M. Mercken, Sarah J. Mitchell et al. · 2013 · Nature Communications · 1.4K citations

Reading Guide

Foundational Papers

Start with Hardie et al. (2012; 4260 citations) for AMPK basics, then Hawley et al. (2003; 1616 citations) for LKB1 activation, and Hardie (2011; 1588 citations) for cellular roles.

Recent Advances

Study Martín-Montalvo et al. (2013) on metformin lifespan effects and Xia et al. (2021) on metabolic reprogramming immune links.

Core Methods

Core techniques include LKB1 complex assays (Hawley et al., 2003), mTOR inhibition via TSC (Brugarolas et al., 2004), and glycolysis targeting (Ganapathy-Kanniappan and Geschwind, 2013).

How PapersFlow Helps You Research AMPK and Tumor Suppression in Cancer

Discover & Search

Research Agent uses citationGraph on Hardie et al. (2012; 4260 citations) to map AMPK-tumor links, then findSimilarPapers reveals LKB1 pathways (Hawley et al., 2003). exaSearch queries 'AMPK tumor suppression cancer' for 250M+ OpenAlex papers, filtering diabetes-cancer overlaps (Giovannucci et al., 2010).

Analyze & Verify

Analysis Agent runs readPaperContent on Hardie (2011) to extract mTOR inhibition details, then verifyResponse with CoVe checks claims against abstracts. runPythonAnalysis plots citation trends from Hardie et al. (2012) vs. Hawley et al. (2003) using pandas; GRADE grades evidence strength for therapeutic claims.

Synthesize & Write

Synthesis Agent detects gaps in AMPK-metformin efficacy post-Giovannucci et al. (2010), flags contradictions in hypoxia responses (Brugarolas et al., 2004). Writing Agent applies latexEditText to draft reviews, latexSyncCitations for 10+ papers, latexCompile for figures, exportMermaid for AMPK-LKB1-mTOR pathway diagrams.

Use Cases

"Analyze AMPK activation data from Hardie papers for tumor suppression stats"

Research Agent → searchPapers('Hardie AMPK') → Analysis Agent → runPythonAnalysis(pandas on citation/expression data) → matplotlib plots of energy sensor efficacy.

"Draft LaTeX review on AMPK in cancer with citations"

Synthesis Agent → gap detection on Hardie et al. (2012) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile(PDF output).

"Find code for AMPK signaling models in cancer papers"

Research Agent → searchPapers('AMPK cancer simulation') → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect(model validation scripts).

Automated Workflows

Deep Research scans 50+ papers from Hardie (2011) baseline, chains citationGraph → findSimilarPapers → structured report on suppression mechanisms. DeepScan applies 7-step CoVe to verify metformin effects (Martín-Montalvo et al., 2013) with GRADE checkpoints. Theorizer generates hypotheses on LKB1-AMPK gaps from Hawley et al. (2003).

Try Doxa for AMPK and Tumor Suppression in Cancer Research

Frequently Asked Questions

What defines AMPK's role in tumor suppression?

AMPK senses low energy to inhibit proliferation and mTOR while promoting autophagy (Hardie et al., 2012; Hardie, 2011).

What are key methods to activate AMPK in cancer?

LKB1-STRAD-MO25 complexes phosphorylate AMPK; metformin indirectly activates via energy stress (Hawley et al., 2003; Martín-Montalvo et al., 2013).

What are pivotal papers on this topic?

Hardie et al. (2012; 4260 citations) on energy sensing; Hawley et al. (2003; 1616 citations) on LKB1 cascade; Giovannucci et al. (2010; 2197 citations) on diabetes-cancer links.

What open problems exist in AMPK-cancer research?

Tumor resistance to AMPK via PI3K/AKT (Huang et al., 2018); inconsistent hypoxia responses (Brugarolas et al., 2004); bridging diabetes therapies to oncology.